Site Search
Google Search
search button
Breaking News: Ryan Disagrees with Trump Allies Over Possibly Impeaching Rosenstein      - | -     Mueller Wants Immunity for Five Secret Witnesses for Manafort Case      - | -     Comey Urging Public to Vote Democratic in the Fall      - | -     Democrats Won't Act to Impeach Trump While Mueller Probe Is Ongoing      - | -     Obama Slams Trump's Politics In Speech Honoring Nelson Mandela     - | -     GOP Congressman Invokes 'The Deep State'
Pfizer Ends Research for New Alzheimer's, Parkinson's Drugs
Get Business & Technology Alerts

viewsViews 905
7 Jan 2018 07:37 PM EST

NEW YORK (Reuters) - Pfizer Inc (PFE.N) is abandoning research to find new drugs aimed at treating Alzheimer’s and Parkinson’s disease, the U.S. pharmaceutical company announced on Saturday. The company said it expects to eliminate 300 positions from the neuroscience discovery and early development programs in Andover and Cambridge, Massachusetts, and Groton, Connecticut, as it redistributes the money spent on research, according to the emailed statement. Pfizer is not making any changes to research and development funding for tanezumab, which is marketed as a treatment for joint pain from osteoarthritis, fibromyalgia treatment Lyrica, or its rare disease program.

Post Your Comment
Excellent Very Good Good Fair Poor



Recently Posted Comments
FREE
AllMediaNY AllMediaNY AllMedaiNY